Literature DB >> 11910176

Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection.

W D Schleuning1.   

Abstract

Plasminogen activators are enzymes found in all vertebrate species investigated so far. Their physiological function is the generation of localized proteolysis in the context of tissue remodeling, wound healing and neuronal plasticity. The common vampire bat (Desmodus rotundus) is a New World species that feeds exclusively on blood. Its saliva contains highly potent plasminogen activators, specialized in rapid lysis of fresh blood clots. Biochemical and pharmacological evidence indicates that these plasminogen activators represent a new class of thrombolytics with pharmacological and toxicological properties superior to human tissue-type plasminogen activator, the clot dissolving agent now most frequently used in medicine. A form of the enzyme produced by recombinant DNA technology is currently employed to test this hypothesis in clinical studies. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11910176     DOI: 10.1159/000048054

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  12 in total

1.  Inhibition of desmoteplase-induced fibrinolytic activity in vitro.

Authors:  Johannes J M L Hoffmann; Oliver Kops
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

2.  Purification and characterization of a fibrinolytic subtilisin-like protease of Bacillus subtilis TP-6 from an Indonesian fermented soybean, Tempeh.

Authors:  Seong-Bo Kim; Dong-Woo Lee; Chan-Ick Cheigh; Eun-Ah Choe; Sang-Jae Lee; Young-Ho Hong; Hak-Jong Choi; Yu-Ryang Pyun
Journal:  J Ind Microbiol Biotechnol       Date:  2006-02-10       Impact factor: 3.346

Review 3.  Clinical trials in acute ischemic stroke.

Authors:  Kiyoshi Kikuchi; Eiichiro Tanaka; Yoshinaka Murai; Salunya Tancharoen
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

Review 4.  Desmoteplase: discovery, insights and opportunities for ischaemic stroke.

Authors:  Robert L Medcalf
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Elucidating nature's solutions to heart, lung, and blood diseases and sleep disorders.

Authors:  Hannah V Carey; Sandra L Martin; Barbara A Horwitz; Lin Yan; Shannon M Bailey; Jason Podrabsky; Jay F Storz; Rudy M Ortiz; Renee P Wong; David A Lathrop
Journal:  Circ Res       Date:  2012-03-30       Impact factor: 17.367

Review 6.  Can the time window for administration of thrombolytics in stroke be increased?

Authors:  Geoffrey A Donnan; David W Howells; Romesh Markus; Danilo Toni; Stephen M Davis
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

7.  Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

Authors:  Nicola Logallo; Christopher E Kvistad; Aliona Nacu; Lars Thomassen
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

Review 8.  Edaravone (Radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke.

Authors:  Kiyoshi Kikuchi; Naoki Miura; Ko-Ichi Kawahara; Yoshinaka Murai; Motohiro Morioka; Paul A Lapchak; Eiichiro Tanaka
Journal:  Biomed Rep       Date:  2012-08-29

Review 9.  Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly.

Authors:  A R Green
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

10.  The "Vampirome": Transcriptome and proteome analysis of the principal and accessory submaxillary glands of the vampire bat Desmodus rotundus, a vector of human rabies.

Authors:  Ivo M B Francischetti; Teresa C F Assumpção; Dongying Ma; Yuan Li; Eliane C Vicente; Wilson Uieda; José M C Ribeiro
Journal:  J Proteomics       Date:  2013-02-11       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.